Triamcinolone acetonide nanoparticles incorporated in thermoreversible gels for age-related macular degeneration

References

• Gopal L, Sharma T. Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration. Ind J Ophthalmol 2007;55:431–435
   PubMedGoogle Scholar
• Sherif Z, Pleyer U. Corticosteroids in ophthalmology: past–present–future. Ophthalmologica 2002;216:305–315
   PubMed Web of Science ®Google Scholar
• Wu WS, Wang FS, Yang KD, et al. Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation. J Investig Dermatol 2006;126:1264–1271
   PubMed Web of Science ®Google Scholar
• Wang YS, Friedrichs U, Eichler W, et al. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefe's archive for clinical and experimental Ophthalmology 2002;240:42–48
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001;119:399–404
   PubMed Web of Science ®Google Scholar
• Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517–1525
   PubMed Web of Science ®Google Scholar
• McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids. Drug Safety 2002;25:33–55
   PubMed Web of Science ®Google Scholar
• Fernández-Robredo P, Sancho A, Johnen S, et al. Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering. J Ophthalmol 2014;2014: Article ID:510285
   PubMed Web of Science ®Google Scholar
• Prevalence of Adult Vision Impairment and Age-Related Eye Diseases in America. Available from: http://www.nei.nih.gov/eyedata/adultvision_usa.asp2010
   Google Scholar
• Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006;58:353–363
   PubMed Web of Science ®Google Scholar
• Regatieri C, Dreyfuss J, Nader H. Experimental treatments for neovascular age-related macular degeneration. In: Ying G-S, ed. Age related macular degeneration – the recent advances in basic research and clinical care. Rijeka, Croatia: InTech; 2012: 83–98
   Google Scholar
• Buschini E, Piras A, Nuzzi R, Vercelli A. Age related macular degeneration and drusen: neuroinflammation in the retina. Prog Neurobiol 2011;95:14–25
   PubMed Web of Science ®Google Scholar
• Bylsma GW, Guymer RH. Treatment of age-related macular degeneration. ClinExp Optomet 2005;88:322–334
   PubMedGoogle Scholar
• Thrimawithana T, Young S, R Bunt C, et al. Drug delivery to the posterior segment of the eye: challenges and opportunities. Drug Deliv Lett 2011;1:40–44
   Google Scholar
• Park YG, Rhu HW, Kang S, Roh YJ. New approach of anti-VEGF agents for age-related macular degeneration. J Ophthalmol 2012;2012:Article ID:637316
   Web of Science ®Google Scholar
• Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–676
   PubMed Web of Science ®Google Scholar
• Group MPS. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol 1993;111:1200–1209
   PubMedGoogle Scholar
• Zhang W, Prausnitz MR, Edwards A. Model of transient drug diffusion across cornea. J Control Release 2004;99:241–258
   PubMed Web of Science ®Google Scholar
• Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006;58:1131–1135
   PubMed Web of Science ®Google Scholar
• Gambhire S, Bhalerao K, Singh S. In situ hydrogel: different approaches to ocular drug delivery. Int J Pharm Pharm Sci 2013;5(2):27–36
   Google Scholar
• Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina 2009;29:875–912
   PubMed Web of Science ®Google Scholar
• Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010;12:348–360
   PubMed Web of Science ®Google Scholar
• Zhou HY, Hao JL, Wang S, et al. Nanoparticles in the ocular drug delivery. Int J Ophthalmol 2013;6:390–396
   PubMed Web of Science ®Google Scholar
• Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol 2013;2:47–64
   PubMedGoogle Scholar
• Sabzevari A, Adibkia K, Hashemi H, et al. Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: In vitro and in vivo studies. Eur J Pharm Biopharm 2013;84:63–71
   PubMed Web of Science ®Google Scholar
• Bu H-Z, Gukasyan HJ, Goulet L, et al. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr Drug Metab 2007;8:91–107
   PubMed Web of Science ®Google Scholar
• Bourges J-L, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Investig Ophthalmol Vis Sci 2003;44:3562–3569
   PubMed Web of Science ®Google Scholar
• Bala I, Hariharan S, Kumar MR. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004;21:387–422
   PubMed Web of Science ®Google Scholar
• Geldenhuys W, Mbimba T, Bui T, et al. Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers. J Drug Target 2011;19:837–845
   PubMed Web of Science ®Google Scholar
• Carroll RT, Bhatia D, Geldenhuys W, et al. Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. J Drug Target 2010;18:665–674
   PubMed Web of Science ®Google Scholar
• Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 2008;16:16–29
   PubMed Web of Science ®Google Scholar
• Li F, Hurley B, Liu Y, et al. Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol J 2012;6:50–58
   Google Scholar
• Nirmal H, Bakliwal S, Pawar S. In-situ gel: new trends in controlled and sustained drug delivery system. Int J PharmTech Res 2010;2:1398–1408
   Google Scholar
• Choi BG, Park MH, Cho S-H, et al. In situ thermal gelling polypeptide for chondrocytes 3D culture. Biomaterials 2010;31:9266–9272
   PubMed Web of Science ®Google Scholar
• Park D, Shah V, Rauck BM, et al. An anti-angiogenic reverse thermal gel as a drug-delivery system for age-related wet macular degeneration. Macromol Biosci 2013;13:464–469
   PubMed Web of Science ®Google Scholar
• Vodithala S, Khatry S, Shastri N, Sadanandam M. Development and evaluation of thermoreversible ocular gels of ketorolac tromethamine. Int J Biopharm 2010;1:39–45
   Google Scholar
• Sutariya V, Miladore N, Geldenhuys W, et al. Thermoreversible gel for delivery of activin receptor-like kinase 5 inhibitor SB-505124 for glaucoma filtration surgery. Pharm Dev Technol 2013;18:957–962
   PubMed Web of Science ®Google Scholar
• Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RS. Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech 2006;7:E80–E86
   Web of Science ®Google Scholar
• Duvvuri S, Janoria KG, Mitra AK. Development of a novel formulation containing poly (d,l-lactide-co-glycolide) microspheres dispersed in PLGA–PEG–PLGA gel for sustained delivery of ganciclovir. J Control Release 2005;108:282–293
   PubMed Web of Science ®Google Scholar
• Moghimipour E, Tafaghodi M, Balouchi A, Handali S. Formulation and in vitro evaluation of topical liposomal gel of triamcinolone acetonide. Res J Pharma Biol Chem Sci. 2013;4:101–107
   Google Scholar
• Gómez-Gaete C, Tsapis N, Besnard M, et al. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm 2007;331:153–159
   PubMed Web of Science ®Google Scholar
• Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm 2007;336:367–375
   PubMed Web of Science ®Google Scholar
• Patel SP, Vaishya R, Mishra GP, et al. Tailor-made pentablock copolymer based formulation for sustained ocular delivery of protein therapeutics. J Drug Deliv 2014;2014: Article ID: 401747. doi:10.1155/2014/401747
   Google Scholar
• Tamboli V, Mishra GP, Mitra AK. Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles. Colloid Polym Sci 2013;291:1235–1245
   PubMed Web of Science ®Google Scholar
• Suen WL, Chau Y. Specific uptake of folate-decorated triamcinolone-encapsulating nanoparticles by retinal pigment epithelium cells enhances and prolongs antiangiogenic activity. J Control Release 2013;167:21–28
   PubMed Web of Science ®Google Scholar
• Yoncheva K, Lambov N. Development of biodegradable poly (alpha-methylmalate) microspheres. Die Pharmazie 2000;55:148–150
   PubMed Web of Science ®Google Scholar
• Yasukawa T, Ogura Y, Tabata Y, et al. Drug delivery systems for vitreoretinal diseases. Progr Retinal Eye Res 2004;23:253–281
   PubMed Web of Science ®Google Scholar
• Kadam RS, Tyagi P, Edelhauser HF, Kompella UB. Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide. Int J Pharm 2012;434:140–147
   PubMed Web of Science ®Google Scholar